ADCs targeting HER2 have been rather prolific in the clinical setting, and one of these agents, trastuzumab deruxtecan, recently received tumor-agnostic approval for HER2-positive (IHC3+) tumors [170]. Here, ERBB2 is linked to neoplasm.